Cerebral grew explosively from a 2020 launch into one of the largest online mental health platforms in the US, peaking at a $4.8 billion valuation in 2021 before a series of regulatory and operational crises forced major restructuring. The DEA opened a federal investigation in 2022 over the platform’s ADHD stimulant prescribing practices, and Cerebral has since substantially scaled back controlled-substance services. As of 2026, Cerebral operates as a more conventional telehealth platform serving depression, anxiety, and limited ADHD care under tighter clinical guidelines. This cerebral review covers what the platform actually does today, current pricing, what changed after the DEA scrutiny, and how Cerebral compares to Brightside Health, Talkspace, and other competitors.
What changed at Cerebral after the DEA investigation
Through 2021-2022, Cerebral aggressively marketed ADHD treatment with same-week prescribing of Schedule II stimulants like Adderall and Ritalin. Reporting by the Wall Street Journal and others documented inconsistent clinical evaluation processes that produced very high rates of stimulant prescribing relative to clinical norms. The DEA opened an investigation in 2022; major pharmacy chains including CVS and Walmart stopped filling Cerebral stimulant prescriptions; and Cerebral suspended Schedule II prescribing entirely in May 2022.
The company restructured significantly through 2022-2023, including layoffs, leadership changes, and a settlement with the Department of Justice. As of 2026, Cerebral has resumed limited ADHD care for some existing patients and certain new cases, but the prescribing protocols are dramatically tighter than the 2021 model. New ADHD patients typically face longer evaluation periods, more documentation, and conservative clinical standards. For broader telehealth context, see our telehealth guide.
Cerebral pricing in 2026
Medication management plan: $99 per month plus medication cost. The plan includes one initial 30-minute video evaluation, monthly follow-up visits, and asynchronous messaging with the prescriber. Medication-and-therapy combined plan: $325 per month with four therapy sessions. Therapy-only plan: $295 per month for four sessions.
Cerebral accepts insurance through partnerships with Aetna, Cigna, Anthem, and select regional plans, though coverage is narrower than Brightside or Talkspace. In-network visits are billed at standard plan copays. Patients should verify coverage with their specific plan before signing up — Cerebral’s insurance footprint shifted substantially during the 2022-2023 restructuring.
Cerebral for ADHD in 2026
ADHD care at Cerebral is significantly different from the pre-2022 model. Schedule II stimulant prescribing follows current DEA telemedicine rules, which have tightened substantially. New ADHD evaluations typically include comprehensive clinical assessment, prior-treatment history review, and may require records from a previous clinician. Some new patients are prescribed non-stimulant alternatives (atomoxetine, guanfacine, bupropion) before Schedule II stimulants are considered.
For existing patients on stable stimulant prescriptions, refill access is more straightforward but still subject to the platform’s tightened clinical protocols. Patients seeking same-week stimulant prescribing for new ADHD diagnoses will find Cerebral less accessible than it was in 2021. The platform is now broadly comparable to other telehealth platforms in ADHD prescribing — neither uniquely permissive nor uniquely restrictive. For ADHD-specific care, dedicated platforms with a narrower focus on ADHD have largely filled the niche Cerebral previously occupied.
Cerebral for depression and anxiety
The bulk of Cerebral’s current patient base is depression, anxiety, and related conditions where Schedule II prescribing isn’t relevant. The clinical model includes initial evaluation, medication selection from standard antidepressants and anti-anxiety medications, and ongoing follow-up. Therapy is offered as an add-on with licensed clinicians.
The clinical depth is decent but not exceptional. Brightside Health has stronger outcome measurement, more rigorous medication selection workflows through PrecisionRx, and better-integrated therapy-and-medication combination. Talkspace has a larger therapy network and broader insurance acceptance. Cerebral occupies a middle position. See our Brightside vs Cerebral and Cerebral vs Talkspace comparisons for detail.
What Cerebral does well
The platform’s strengths in 2026 are different from its 2021 strengths. Same-week first-appointment availability is genuine — patients can typically be seen within 5-7 days, which is faster than most in-person psychiatric care in many markets. The patient experience and app design are solid, with good symptom tracking and easy messaging.
The medication-and-therapy combination plan is reasonably integrated, particularly for depression and anxiety. Patients who want both modalities through one platform get coordinated care that’s harder to achieve when running parallel BetterHelp + separate psychiatry. Pricing is competitive with Brightside, though without the same clinical depth.
Where Cerebral falls short
The brand still carries reputational damage from the 2022 events. While the clinical practices have materially improved, public trust hasn’t fully recovered, and many clinicians remain skeptical of the platform. For patients comfortable with the current state, this matters less; for patients comparing platforms based on reputation, Brightside or Talkspace are easier choices.
The platform’s focus has narrowed since 2022, which limits some use cases. Substance use disorder treatment, severe eating disorders, and complex psychiatric cases are appropriately outside the platform’s scope but were sometimes marketed pre-2022. Patients with these needs should look at specialized programs rather than Cerebral. Insurance acceptance is also narrower than Brightside or Talkspace, limiting options for some patients.
Cerebral vs Brightside, Talkspace, and BetterHelp
Compared to Brightside Health, Cerebral is similar in pricing and patient experience but weaker on clinical infrastructure and outcome measurement. Brightside is the better choice for clinically rigorous integrated psychiatric care. Compared to Talkspace, Cerebral has slightly better integration of therapy and medication while Talkspace has broader insurance acceptance and a larger therapist network.
Compared to BetterHelp, Cerebral offers medication management which BetterHelp doesn’t. For pure therapy without medication, BetterHelp is cheaper and more flexible. For integrated medication-and-therapy care, Cerebral offers something BetterHelp can’t. See our detailed Cerebral vs Talkspace head-to-head.
Frequently Asked Questions
Is Cerebral still operating in 2026?
Yes. Cerebral continues to operate after the 2022-2023 restructuring. The clinical model is materially different from the pre-2022 platform, with tighter ADHD prescribing protocols and a broader focus on depression and anxiety care.
Does Cerebral prescribe Adderall?
For some existing patients on stable prescriptions, yes. For new ADHD diagnoses, Cerebral’s prescribing standards have tightened substantially since 2022 and follow current DEA telemedicine rules. New stimulant prescriptions often involve longer evaluation, prior-treatment history review, and may include non-stimulant trials first.
Does Cerebral take insurance?
Yes, with select major insurers including Aetna, Cigna, Anthem, and some regional plans. Coverage is narrower than Brightside or Talkspace. Verify with your specific plan before signing up.
How is Cerebral different from Brightside?
Brightside has more rigorous clinical infrastructure, better outcome measurement, and stronger published outcomes data. Cerebral has comparable pricing and patient experience but is generally considered the less clinically rigorous of the two options.
Is Cerebral safe?
The platform is HIPAA-covered, the clinicians are appropriately licensed, and the prescribing practices have tightened substantially since 2022. As of 2026, Cerebral meets standard clinical care expectations. Patients comparing platforms based on past reputation may still prefer Brightside or Talkspace.
The bottom line on Cerebral
Cerebral in 2026 is a different company than the 2021 platform that grew explosively and then ran into regulatory trouble. The current clinical model is more conservative, the prescribing protocols are appropriately constrained, and the patient experience is solid. For patients with depression or anxiety seeking integrated medication and therapy, Cerebral is reasonable but not the best in class — Brightside Health offers more clinical rigor and better outcome data. For ADHD specifically, the platform is no longer the easy-access option it once was, and dedicated ADHD-focused platforms or in-person care are now better choices for new diagnoses.